MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD

ASD Clinical Trial

— IRM-ET  

Official title:

MRI-Eye Tracking Pairing, a Tool for Assessing Social Cognition in Children With ASD

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05194254
• Other study ID #: PI2021_843_0194
• Status: Recruiting
• Phase: N/A
• Start date: January 4, 2022
• Est. completion date: May 2024

Study information

• Verified date: February 2023
• Source: Centre Hospitalier Universitaire, Amiens
• Contact: Jean-Marc Constans, Pr
• Phone: 03 22 08 75 15
• Email: constans.jean-marc[@]chu-amiens.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Most studies use static visual percepts that are less representative of joint attention versus an ecological environment. This has the consequence of decreasing the perception of an interaction with a social partner, which is an essential step in achieving joint attention. The originality of this study is to improve the design of visual percepts (in the form of video) in order to mimic an ecological environment as much as possible by using MRI-ET coupling. The second originality of this study is the longitudinal exploration of the neurodevelopment of social cognition in autistic children. Studies by the Redcay and Oberwelland teams observe different activations at different ages. The hypothesis is that the perception of joint attention varies over time in people with ASD. To date, there are no studies to determine the influence of childhood neurodevelopment in autistic people on the perception of joint attention. It would be unprecedented to use the MRI-ET pairing as a tool for assessing social cognition as a function of the development of children with ASD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 68
• Est. completion date: May 2024
• Est. primary completion date: January 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 10 Years to 20 Years

Eligibility

Inclusion Criteria:

For the group of people with Autism Spectrum Disorders (experimental group):

• Age between 10 to 20 years old
• Diagnosis of ASD (CARS) = 30 performed at inclusion
• IQ test evaluation (regardless of the result) performed by a trained psychologist
• Obtaining informed oral and written consent after appropriate information
• Obtaining informed oral and written consent from the legal guardian after information
• Be affiliated with social security
• No contraindication to magnetic resonance imaging

For the TD (Typical Development) group of people (control group):

• Age between 10 to 20 years old
• Diagnosis of ASD (CARS) <30 performed at inclusion
• IQ test evaluation (regardless of the result) performed by a trained psychologist
• Obtaining informed oral and written consent after appropriate information
• Obtaining informed oral and written consent from the legal guardian after information
• Be affiliated with social security
• No contraindication to magnetic resonance imaging Exclusion Criteria:

For all groups:

• Age outside the range 10 to 20 years
• Person with a contraindication to MRI (including claustrophobia, pace maker, neurosurgical clips, vascular clips, heart valves, ventriculoperitoneal valves, cochlear implant, neurostimulator, intraocular metal shards, joint prosthesis, etc.)
• Person suffering from major obesity (> 140 kg) not allowing him to enter the tunnel of the MRI machine (diameter <70cm)
• Pregnant or breastfeeding woman
• Person under guardianship or guardianship or deprived of liberty by a judicial or administrative decision

For TD people (control group):

• Person with psychiatric disorders such as attention disorder with or without hyperactivity, depression, bipolar disorder and schizophrenia.
• Person with a neurological history such as epilepsy and / or neurovascular accident.

Related Conditions & MeSH terms

• ASD
• Eye Tracking
• Functional Magnetic Resonance Imaging
• Social Cognition

Intervention

Other:
• MRI-ET
coupled fMRI and Eye Tracking tools

Locations

Country	Name	City	State
France	CHU Amiens Picardie	Amiens	Picardie

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire, Amiens

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	difference of mapping IRM-ET results between both patient groups	both patient groups are : the group of people with Autism Spectrum Disorders and Typical Development group of people	one day